Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin

GlobeNewswire April 3, 2024

ObsEva Announces Update on Board of Directors

GlobeNewswire March 19, 2024

ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023

GlobeNewswire February 28, 2024

Geneva Court Grants Temporary Moratorium to ObsEva

GlobeNewswire January 31, 2024

ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

GlobeNewswire November 30, 2023

Organon Returns Ebopiprant to XOMA

GlobeNewswire October 27, 2023

ObsEva Files half Year 2023 Financial Statements

GlobeNewswire September 27, 2023

ObsEva Recovers Full Worldwide Rights on Nolasiban

GlobeNewswire July 13, 2023

Annual General Meeting 2023

GlobeNewswire June 8, 2023

ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer

GlobeNewswire May 2, 2023

ObsEva Announces Change of Central Securities Depositary

GlobeNewswire April 20, 2023

ObsEva Files Year End 2022 Financial Statements

GlobeNewswire March 31, 2023

ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023

GlobeNewswire March 15, 2023

ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland

GlobeNewswire March 13, 2023

ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland

GlobeNewswire February 24, 2023

ObsEva Announces Dismissal of Moratorium Proceedings

GlobeNewswire December 19, 2022

ObsEva Evidences Compliance with Nasdaq's Stockholder's Equity Rule and Announces Moratorium Dismissal Request Filing

GlobeNewswire December 14, 2022

ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares

GlobeNewswire December 9, 2022

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire December 1, 2022

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

GlobeNewswire November 22, 2022